Mission Therapeutics Limited

Royaume‑Uni

 
Quantité totale PI 80
Rang # Quantité totale PI 16 849
Note d'activité PI 2,5/5.0    43
Rang # Activité PI 17 393
Classe Nice dominante Produits chimiques destinés à l'...

Brevets

Marques

39 0
10 0
30 0
1
 
Dernier brevet 2025 - Substituted n-cyanopyrrolidines ...
Premier brevet 2015 - Methods for exploiting synthetic...
Dernière marque 2011 - MISSION THERAPEUTICS
Première marque 2011 - MISSION THERAPEUTICS

Industrie (Classification de Nice)

Derniers inventions, produits et services

2022 Invention Substituted n-cyanopyrrolidines with activity as usp30 inhibitors. The present invention relates...
Invention Substituted n-cyanopyrrolidines with activity as usp30 inhibitors. The present invention relates ...
Invention Compounds. The present invention relates to novel compounds and methods for the manufacture of in...
Invention 1-cyano-pyrrolidine compounds as usp30 inhibitors. The present invention relates to novel compou...
Invention 1-cyano-pyrrolidine derivatives as dub inhibitors. 6 alkyl; A represents an optionally further su...
2021 Invention Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors. The presen...
Invention N-cyanopyrrolidines with activity as usp30 inhibitors. The present invention relates to a class o...
Invention Compounds. 2, X, L and A are as defined herein.
Invention 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbo...
Invention N-cyanopyrrolidines with activity as usp30 inhibitors. The present ...
Invention N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and th...
Invention N-cyanopyrrolidines with activity as usp30 inhibitors. The present invention relates to a class ...
2020 Invention Substituted cyanopyrrolidines with activity as usp30 inhibitors. The present invention relates t...
Invention Substituted cyanopyrrolidines with activity as usp30 inhibitors. The present invention relates to...
Invention Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors. The present...
Invention Cyanopyrrolidines as dub inhibitors for the treatment of cancer. The present invention relates to...
Invention 1-cyano-pyrrolidine compounds as usp30 inhibitors. 10, Z, Y and m are as defined herein.
2019 Invention 1-cyano-pyrrolidine compounds as usp30 inhibitors. 12, Z, Y and m are as defined herein.
Invention Cyanopyrrolidines as usp30 inhibitors and fibrosis treatment. The present invention relates to n...
Invention Cyanopyrrolidines as usp30 inhibitors and fibrosis treatment. The present invention relates to no...
2018 Invention Substituted cyanopyrrolidines with activity as dub inhibitors. The present invention relates to a...
Invention Substituted cyanopyrrolidines with activity as dub inhibitors. Substituted Cyanopyrrolidines with...
Invention Sulfonamide-substituted cyanopyrrolidines with activity as dub inhibitors. The present invention ...
2017 Invention Cyano-substituted heterocycles with activity as inhibitors of usp30. The present invention relate...
Invention Cyanopyrrolidine derivatives with activity as inhibitors of usp30. The present invention relates ...
Invention Cyano-subtituted heterocycles with activity as inhibitors of usp30. The present invention relates...
Invention 4,6 dihydropyrrolo [3,4-c] pyrazole-5 (1h)-carbonitrile derivates for treating cancer. 6 cycloalk...
Invention 2-cyanoisoindoline derivatives for treating cancer. The invention relates to novel compounds of f...
Invention Compounds. The present invention relates to novel compounds of formula (I) and methods for the ma...
2016 Invention 1-cyano-pyrrolidine derivatives as inhibitors of usp30. 3, m, L and X are as defined herein.
Invention Methods of screening and treatment with usp4 inhibitors. The present application relates to mater...
2011 P/S Chemical and proteins for chemical and biological drug discovery, lead identification and diagnos...